Suppression of MiR130a-3p Using CRISPR/Cas9 Induces Proliferation and Migration of Non-Small Cell Lung Cancer Cell Line
Abstract
BACKGROUND: Molecular alterations of microRNA130a (miR130a) are observed in many types of cancers, including non-small cell lung cancer (NSCLC). However, the role of miR130a in NSCLC has been poorly studied.
METHODS: In this study, clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 was utilised to knockdown miR130a. The gRNA was designed to target the stem loop, 3’ and 5’ sites of miR130a and stably expressed in A549 cells. Post-treatment, mature levels of miR130a-3p and 5p were quantified, and proliferation and migration assays were conducted.
RESULTS: Result showed significant suppression of miR130a-3p and -5p by two and three-fold respectively, when the CRISPR/Cas9 targeted at the 3’ site and stem loop of the miR130a gene. Suppression of miR130a-3p significantly increased the growth and migration of A549 cells, but no significant changes were observed in cells with suppressed expression of miR130a-5p.
CONCLUSION: Our encouraging results highlight that the suppression of the miR130a is achievable using CRISPR/Cas9, and suppression of the miR-130a-3p could play an important role in the regulation of NSCLC.
KEYWORDS: miR130a, CRISPR-Cas9, non-small cell lung cancer
Full Text:
PDFReferences
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer. 2018; 68: 394-424, CrossRef.
Ohno Y, Koyama H, Yoshikawa T, Matsumoto S, Sugimura K. Lung cancer assessment using MR imaging. Magn Reson Imaging Clin N Am. 2015; 23: 231-44, CrossRef.
Wei D, Peng JJ, Gao H, Zhang T, Tan Y, Hu YH. ALDH1 expression and the prognosis of lung cancer: a systematic review and meta-analysis. Heart Lung Circ. 2015; 24: 780-8, CrossRef.
Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017; 389: 299-311, CrossRef.
He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5: 522-31, CrossRef.
Chakraborty C, Sharma AR, Sharma G, Sarkar BK, Lee SS. The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. Oncotarget. 2018; 9: 10164-74, CrossRef.
Zhang L, Yang X, Lv Y, Xin X, Qin C, Han X, et al. Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer. Sci Rep. 2017; 7: 46186, CrossRef.
Suresh S, McCallum L, Lu W, Lazar N, Perbal B, Irvine AE. MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML. J Cell Commun Signal. 2011; 5: 183-91, CrossRef.
Zhou P, Jiang W, Wu L, Chang R, Wu K, Wang Z. miR-301a is a candidate oncogene that targets the homeobox gene Gax in human hepatocellular carcinoma. Dig Dis Sci. 2012; 57: 1171-80, CrossRef.
Liu L, Nie J, Chen L, Dong G, Du X, Wu X, Tang Y, Han W. The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PLoS One. 2013; 8: 55532, CrossRef.
Ramalho-Carvalho J, Martins JB, Cekaite L, Sveen A, Torres-Ferreira J, Graça I, et al. Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. Cancer Lett. 2017; 385: 150-9, CrossRef.
Chen X, Zhao M, Huang J, Li Y, Wang S, Harrington CA, et al. microRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1. J Cell Biochem. 2018; 119: 4945-56, CrossRef.
Kong X, Zhang J, Li J, Shao J, Fang L. MiR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells. Biochem Biophys Res Commun. 2018; 501: 486-93, CrossRef.
Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother. 2010; 64: 399-408, CrossRef.
Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008; 111: 478-86, CrossRef.
Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2010; 46: 298-311, CrossRef.
Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, et al. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221&222. Oncogene. 2012; 31: 634-42, CrossRef.
Wei MC, Wang YM, Wang DW. miR-130a-Mediated KLF3 can inhibit the growth of lung cancer cells. Cancer Manag Res. 2021; 13: 2995-3004, CrossRef.
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013; 8: 2281-308, CrossRef.
Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science. 2013; 339: 823-6, CrossRef.
Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014; 11: 783-4, CrossRef.
Geer LY, Marchler-Bauer A, Geer RC, Han L, He J, He S, et al. The NCBI BioSystems database. Nucleic Acids Res. 2010; 38: D492-6, CrossRef.
Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer. 2009; 104: 1168-77, CrossRef.
Goetsch KP, Niesler CU. Optimization of the scratch assay for in vitro skeletal muscle wound healing analysis. Anal Biochem. 2011; 411: 158-60, CrossRef.
Liu Y, Li Y, Wang R, Qin S, Liu J, Su F, et al. MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells. Journal of Experimental & Clinical Cancer Research, 2019, 35: 19, CrossRef.
Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM. Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3′ UTR evolution. Cell. 2005; 123: 1133-46, CrossRef.
Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA. 2008; 14: 1539-49, CrossRef.
Piskounova E, Viswanathan SR, Janas M, LaPierre RJ, Daley GQ, Sliz P, et al. Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. Int J Biol Chem. 2008; 283: 21310-4, CrossRef.
Rybak A, Fuchs H, Smirnova L, Brandt C, Pohl EE, Nitsch R, et al. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol. 2008; 10: 987-93, CrossRef.
Lund E, Güttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science. 2004; 303: 95-8, CrossRef.
Zeng Y, Cullen BR. Structural requirements for pre-microRNA binding and nuclear export by Exportin 5. Nucleic Acids Res. 2004; 32: 4776-85, CrossRef.
Boll K, Reiche K, Kasack K, Mörbt N, Kretzschmar AK, Tomm JM, et al. miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene. 2013; 32: 277-85, CrossRef.
Cao Z, Cheng W, Lou T, Zhang N, Pan J, Yin Q, et al. Inhibition of miR-130a expression promotes metastasis of lung squamous carcinoma cells. Int J Clin Exp. 2016; 9: 1612-20, article.
Wang T, Wei J, Xu L, Jia R, Guo C. MiR-130a regulates the proliferation and metastasis of HCC cells through targeting ZEB1/2. Int J Clin Exp Pathol. 2017; 10: 2744-53.
Wang XC, Du LQ, Zhang H, Wang YY, Wu HY, Li DG, et al. Expression of miRNA-130a in nonsmall cell lung cancer. Am J Med Sci. 2010; 340: 385-8, CrossRef.
Zhang W, Ding Q, Zhang N. MiR-130a inhibits cell proliferation and migration via targeting TGFA in non-small cell lung cancer cells. Int J Clin Exp Pathol. 2017; 10: 117-27, article.
Tang C, Yang Z, Chen D, Xie Q, Peng T, Wu J, et al. Downregulation of miR-130a promotes cell growth and epithelial to mesenchymal transition by activating HMGB2 in glioma. Int J Biochem Cell Biol. 2017; 93: 25-31, CrossRef.
Zhu X, Lin Z, Du J, Zhou X, Yang L, Liu G. Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia. Mol Cell Biochem. 2014; 390: 75-84, CrossRef.
Abdollah NA, Zulkifle N, Razak SRA. Computational prediction of miR130a target genes in cancer. Malaysian J Med Health Sci. 2020; 16(Suppl 2): 51-9, article.
Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA. The COSMIC cancer gene census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018; 18: 696-705, CrossRef.
Khaled WT, Lee SC, Stingl J, Chen X, Ali HR, Rueda OM, et al. BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells. Nat Commun. 2015; 6: 5987, CrossRef.
Wang S, Qiu J, Liu L, Su C, Qi L, Huang C, et al. CREB5 promotes invasiveness and metastasis in colorectal cancer by directly activating MET. J Exp Clin Cancer Res. 2020; 39: 168, CrossRef.
Sun Z, Liu C, Jiang WG, Ye L. Deregulated bone morphogenetic proteins and their receptors are associated with disease progression of gastric cancer. Comput Struct Biotechnol J. 2020; 18: 177-88, CrossRef.
Zhu L, Pan R, Zhou D, Ye G, Tan W. BCL11A enhances stemness and promotes progression by activating Wnt/β-catenin signaling in breast cancer. Cancer Manag Res. 2019; 11: 2997-3007, CrossRef.
Guo K, Wang P, Zhang L, Zhou Y, Dai X, Yan Y, et al. Transcription factor POU4F2 promotes colorectal cancer cell migration and invasion through hedgehog-mediated epithelial-mesenchymal transition. Cancer Sci. 2021; 112: 4176-86, CrossRef.
Li SZ, Zhen F, Li J, Shu QP, Zhang HH, Xu J, et al. Nemo-like kinase (NLK) primes colorectal cancer progression by releasing the E2F1 complex from HDAC1. Cancer Lett. 2018; 431: 43-53, CrossRef.
Hu Y, Yang L, Zhang M, Huang Z, Lin J, Zhang N. Expression and clinical relevance of SPOPL in medulloblastoma. Oncol Lett. 2017; 14: 3051-6, CrossRef.
Li JD, Feng QC, Qi Y, Cui G, Zhao S. PPARGC1A is upregulated and facilitates lung cancer metastasis. Exp Cell Res. 2017; 359: 356-60, CrossRef.
Wu RC, Young IC, Chen YF, Chuang ST, Toubaji A, Wu MY. Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer. Nat Commun. 2019; 10: 4332, CrossRef.
Ma F, Xie Y, Lei Y, Kuanh Z, Liu X. The microRNA-130a-5p/RUNX2/STK32A network modulates tumor invasive and metastatic potential in non-small cell lung cancer. BMC Cancer. 2020; 20: 580, CrossRef.
Fan Q, Huang T, Sun X, Yang X, Wang J, Liu Y, et al. miR‑130a‑3p promotes cell proliferation and invasion by targeting estrogen receptor α and androgen receptor in cervical cancer. Exp Ther Med. 2021; 21: 414, CrossRef.
Alrashed MM, Ahmad M, Yongmei W, Xiuyeng W. Differential expression of miR-130a-3p modulate ovarian epithelial carcinoma (OEC) cell development and could be a biomarker for OEC. J Reprod Immunol. 2021; 145: 103310, CrossRef.
Shi J, Wang H, Feng W, Huang S, An J, Qui Y, Wu K. MicroRNA-130a targeting hypoxia-inducible factor 1 alpha suppresses cell metastasis and Warburg effect of NSCLC cells under hypoxia. Life Sci. 2020; 255: 117826, CrossRef.
Jing J, Zhao X, Wang J, Li T. Potential diagnostic and prognostic value and regulatory relationship of long noncoding RNA CCAT1 and miR-130a-3p in clear cell renal cell carcinoma. Cancer Cell Int. 2021; 21: 68, CrossRef.
DOI: https://doi.org/10.18585/inabj.v13i4.1670
Copyright (c) 2021 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
